For patients with type 2 diabetes mellitus, semaglutide is associated with a reduced risk for a first-time Alzheimer disease (AD) diagnosis compared with other antidiabetic medications, according to a ...

The study links early-life sugar exposure to chronic disease risk, suggesting that sugar restriction could enhance health and ...

Discover how vitamin D may hold the key to managing type 2 diabetes with new insights into its impact on insulin and glucose ...

Alzheimer's disease (AD) is a progressive brain disorder that gradually destroys memory and cognitive abilities, affecting ...

Data from the SENZA-PDN trial showed 10 kHz SCS yielded long-term, clinically meaningful reductions in HbA1c and weight in patients with PDN and T2D.

The findings are based on data gathered after the Second World War in the UK, around the time when sugar rationing ended.

Researchers use real-world data in the United States to evaluate the protective role of semaglutide against Alzherimer’s ...

SGLT2i是近年来备受瞩目的一类新型降糖药，其发挥肾脏保护作用的核心机制是通过抑制肾小管SGLT2，Na+的重吸收减少，导致远曲小管中Na+浓度升高，致密斑感受到Na+浓度升高后调节肾素的释放，收缩肾小球入球小动脉，降低囊内压，重建管球反馈10。此 ...

iCaReMe China研究是一项具有里程碑意义的真实世界研究，由北京大学人民医院发起， 在全国范围开展的一项评估中国T2DM患者管理和医疗服务质量的多中心注册登记研究。该研究通过描述真实世界中T2DM患者的临床特征和治疗模式，以了解中国的糖尿病管理策略、区域差异、相关决定因素和患者结局。 iCaReMe ...

The use of glucagon-like peptide 1 (GLP-1) receptor agonists in adults with type 2 diabetes mellitus (T2DM) was not ...

➤ONWARDS 3 研究结果显示，在既往未使用胰岛素的T2DM患者中，依柯胰岛素组降低HbA1c水平较德谷胰岛素组更优，并且低血糖发生风险与德谷胰岛素组相当。

Semaglutide was linked to a significantly reduced risk, most strongly compared with insulin and most weakly with other GLP-1 RAs.